Bone grafting is a surgical procedure, which replaces missing bone and promotes new bone growth. It is also used to maintain bone structure after tooth extraction. Bone grafting is performed to build a foundation so as to successfully place dental implants. There are a variety of sources of bone grafting material such as Allograft, Xenograft, and Synthetic bone graft. In Allograft, laboratory-processed human bone is used, which is taken from a deceased donor that comes from a tissue bank. Xenograft bone graft is derived bone graft obtained from other species. In Synthetically derived graft, Hydroxyapatite and Tricalcium phosphate (TCP) are most commonly used by manufacturers. Hydroxyapatite (HA) is a naturally occurring mineral form of calcium apatite and Tricalcium phosphate is biocompatible and acts as an osteoconductive scaffold. Dental membrane acts as a barrier in many bone grafts for dental implants. The membrane is placed under the gum but over the bone. Dental membrane protects and stabilizes the bone graft.
Get Sample Copy at: https://www.coherentmarketinsights.com/insight/request-sample/1143
Dental membrane and bone graft substitute market is primarily driven by growing geriatric population. According to National Institute of Dental and Craniofacial Research, in 2014, adults from age 20 to 64 have an average of 24.92 remaining teeth and hence growing geriatric population is expected to favor the growth of the dental membrane and bone graft substitute market. According to Centers for Disease Control (CDC) NHANES Study, in 2016, the U.S. had more than 120 million people with one teeth missing and about 35 million people (i.e. approximately 10% of U.S. population) with all of their teeth missing in one or both jaws. American College of Prosthodontics (ACP) expects this number to further increase in next two decades. Increasing population with missing one or more teeth is expected to drive the growth of dental bone graft substitutes market. Moreover, increasing dentist population and growing awareness about dental procedures are expected to support the market growth in near future.
Raising awareness of periodontology is expected to drive the growth of dental membrane and bone graft substitute market
Gum disease leads to the serious health problem affecting half of all people aged over 35 and above and it is also linked with various chronic diseases such as diabetes, cardiovascular disease, and other chronic non communicable conditions. According to the Centers for Disease Control and Prevention (CDC), in 2010, an estimated around 48% i.e. around 64 million adults in the U.S. had periodontal disease. In order to control serious disease linked with gum diseases, in 2014, The American Academy of Periodontology (AAP), launched national consumer awareness campaign in the U.S. to educate about the prevention and early diagnosis of periodontal disease. In 2016, The British Society of Periodontology (BSP) launched an innovative campaign in the U.K to raise the awareness of gum disease and its impact on general health. Thus, the initiative taken by health authorities to increase the awareness of gum disease among population is expected to aid in growth of the dental membrane and bone graft substitute market over the forecast period.
The global dental membrane and bone graft substitute market was valued at US$ 700.2 million in 2017 and is expected to witness a robust CAGR of 9.4% over the forecast period (2017 – 2025).
Development of innovative bone grafting products is expected to propel growth of the market
Companies are developing innovative technology that provide safety, high comfort, and offers a wide range of treatment options. For instance, in 2014, Nobel Biocare Services AG had launched new creos allograft regenerative solution in the U.S. The new creos allograft portfolio consist of regenerative products in three different core products i.e. in demineralized bone matrix putty, barrier membrane, and particulate bone graft. The new creos allograft can easily adapt to the graft site and it is a reliable and effective barrier to soft tissue ingrowth during the curative process and can easily adapt to the graft site. Moreover, in 2016, Antibe Therapeutics Inc., a subsidiary company of Citagenix Inc. had launched Neomem FlexPlus, a barrier membrane for regenerative procedures in Canada, Neomem FlexPlus a single layer collagen membrane that make surgical placement easy. Thus, the advance technology implemented by manufacturer in the dental membrane and bone graft substitute product is expected to propel the growth of dental membrane and bone graft substitute market growth over the forecast period.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/1143
Some of the major players operating in the dental membrane and bone graft substitute market include Citagenix Inc, Straumann AG, Geistlich, Dentsply International, Zimmer Biomet, Medtronic Plc., BioHorizons IPH, Inc., ACE Surgical Supply Company, Inc., RTI Surgical, Inc., and Osteogenics Biomedical.
This post was originally published on Trading Herald